“Development of galenic formulations for chemotherapy-induced mucositis”

Oral mucositis (OM) is a common complication in patients undergoing chemotherapy or radiotherapy. This study investigates the development of personalized galenic formulation to improve symptom management. This is because standard treatment provides limited relief and currently there are limited options. Therefore, the aim of this study was to investigate other therapeutic options, starting from active ingredients. From the literature 4 ingredients found promising results, such as zinc chloride, lidocaine, nystatin and doxepin. In fact, the literature demonstrated that in order to treat mucositis pain management was essential, and this could be obtained with traditional analgesics such as lidocaine and more innovative molecules like doxepin that displayed local anaesthetic properties. Lastly, recent studies show that zinc chloride has potential anti-inflammatory effects, which is crucial to manage OM. From these active ingredients, three galenic preparations were developed: Nystatin and lidocaine 2% pastilles Doxepin based mouthwash Zinc chloride-based mouthwash This formulation was administered to patients affected by oral mucositis. Afterward a questionnaire was used to evaluate different factors of the formulation such as relief, tolerability, taste and perceived effectiveness. From the data gathered, it was evident that the majority of patients reported moderate pain relief, good palatability, and minimal side effects. Lozenges were particularly favoured for their ease of application compared to other options. These findings support the use of galenic formulations as a promising alternative for mucositis management.